Understanding and targeting resistance mechanisms in NSCLC
Nature Reviews Cancer 17, 637 (2017).
doi:10.1038/nrc.2017.84
Authors: Julia Rotow & Trever G. Bivona
The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances,
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Julia Rotow Trever G. Bivona Tags: Review Source Type: research